Nepal | June 04, 2020

No-deal Brexit could deepen Europe’s shortage of medicines: experts

Share Now:

BRUSSELS: As the October 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit.

Britain’s food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit. Pharmaceutical companies have expressed similar concerns about medicines, and some have reserved air freight capacity to fly in supplies if needed.

But the impact on medical supplies will also be felt beyond Britain. About 45 million packs of medicines are shipped from Britain to the rest of the bloc every month, in trade worth nearly 12 billion pounds ($14.5 billion) in 2016, according to a British parliament report.

Illustration photo shows various medicine pills in their original packaging in Brussels, Belgium August 9, 2019. Photo: Reuters

Experts say some disruption is inevitable if Britain leaves the EU without a deal. British Prime Minister Boris Johnson has said he will lead his country out of the EU on October 31 without a deal if the EU refuses to negotiate a new divorce agreement.

Some drugs might not have the required regulatory approval by then to continue being brought in from Britain. About 1 billion packs go in one direction or the other each year, industry data show.

Increased customs controls at ports and other borders between Britain and the EU could also disrupt supplies of drugs and the chemical compounds needed to produce them, regulators and industry representatives say.

“Despite intensive preparation by industry for every scenario, a no-deal Brexit risks disruption to the supply of medicines” throughout the EU, Andy Powrie-Smith, an official at the European Federation of Pharmaceutical Industries and Associations, told Reuters.

The EU drugs regulator, the European Medicines Agency (EMA), said the bloc is well prepared for Brexit and has finalised authorizations for nearly all the 400 drugs under its watch that required further clearing because of Britain’s impending departure.

But authorization is pending for three medicines that need EU-wide license, an EMA official said without identifying them.

Other essential medicines could also be blocked because of supervisory hurdles because of Brexit, EMA data show.

The agency is the only body that can authorize sales in the 28-country EU of new drugs to treat the most common and serious diseases, including cancer, diabetes and flu.


Many other medicines authorized at national level could also be at risk. Nearly 6,000 of these drugs need to go through a new licensing process after Brexit.

The EMA official said the agency did not have “a full picture” of the situation in all EU states for nationally authorized medicines.

The Netherlands said in February that 50 “critical” drugs were at risk of shortages in the event of a no-deal Brexit. Concerns about most of those drugs have since been resolved, a spokesman for the Dutch health ministry said, but problems could arise for less essential medicines.

In a report in June, the EU’s executive European Commission included medicines and medical devices in a list of sectors for which “continued and particular vigilance” was needed.

Many EU states already face shortages of some medicines because of problems with production, regulators or distribution.

A survey of 21 European countries showed that all of them experienced shortages of medicines last year, according to the Pharmaceutical Group of the European Union, a pharmacists’ trade body. Vaccines were among the drugs most frequently cited as being in short supply.

Britain will need to authorize hundreds of new medicines on sale now only thanks to EU-wide registrations. Britain imports about 37 million medicine packs every month from the EU, industry figures show.

Britain is also losing supervisory and clinical-trial capacities as many operations have already moved to the EU to remain able to test and approve drugs for the EU market after Brexit. This trend could shrink the local pharmaceutical industry and lead to tighter supplies and higher costs.

EU countries face the same logistical hurdles for their imports from Britain.

In the event of Brexit without a divorce deal, “there will be some problems and delays in the supply chain due to border protocols, but I think we will be able to manage,” said Eric Van Nueten, the chief executive officer of Febelco, Belgium’s largest wholesale trader of medicines.

Follow The Himalayan Times on Twitter and Facebook

Recommended Stories:

More from The Himalayan Times:

St Xavier's in dispute with Godavari local level over establishment of ward office in its premises

KATHMANDU: The St Xavier’s School, Godavari, has gotten into a dispute with the local level after the latter reportedly established its ward office and a quarantine centre at the teachers' quarters in the school premises on Tuesday evening. Local representatives on Tuesday afternoon established Read More...

India approves Gilead's remdesivir to treat severe COVID-19 cases

BENGALURU: India's government has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients. Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical Read More...

Agriculture: Can it provide relief to returnee migrants and vulnerable populations?

Ram Bahadur Pariyar from Kaski district recently returned from Qatar after losing his job and plans to return to agriculture. “I will grow ginger and turmeric on my farm, they don’t go bad easily, and the market value is good,” he said. The COVID-19 pandemic and ensuing global recession thr Read More...

Nepal government opens 20 crossing points along Nepal-India border to ease entry of its citizens

KATHMANDU: Nepalis in India willing to return home will now be allowed entry to the country via twenty entry points along Nepal-India border. Addressing all Nepalis in India, Embassy of Nepal in India said on Wednesday that movement through 20 entry points -- Pashupatinagar (Illam), Kakadvitta (J Read More...

Worldwide coronavirus cases cross 6.39 million, death toll over 379,400

At least 6,390,543 people have been reported infected with the novel coronavirus globally and 379,433 have died, a Reuters tally shows. Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019.   Read More...

Seven additional cornavirus cases confirmed in Sunsari

SUNSARI: As many as seven new cases of coronavirus infection have been identified in Bhokraha Narsingh Rural Municipality of Sunsari district, on Wednesday. The infections were confirmed through the PCR tests conducted in 40 swab samples at BP Koirala Institute of Health Science. Authorities h Read More...

Hepatitis patient being treated in quarantine facility in Bajura

BAJURA: An 18-year-old male suffering from hepatitis is presently staying inside a quarantine facility of Bajura district and being treated there in lack of a better alternative. The teenager from Budhiganga Municipality-2 reached Bajura from India on May 30. He is stationed at a make-shift quara Read More...

UK doctors to trial ibuprofen in COVID-19 patients with breathing difficulties

LONDON: British doctors are trialling a formulation of anti-inflammatory ibuprofen to see if it reduces respiratory failure in patients with severe symptoms of COVID-19. The trial involves a particular formulation of ibuprofen, which researchers said had been shown to be more effective than s Read More...